Ignite Creation Date:
2024-05-06 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 2:31 PM
Study NCT ID:
NCT05352542
Status:
TERMINATED
Last Update Posted:
2023-07-11
First Post:
2022-04-01
Brief Title:
GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
Sponsor:
jianming xu
Organization:
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Study Overview
Official Title:
A Phase I Clinical Trial for Evaluating the Safety Tolerance and Efficacy of GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
Status:
TERMINATED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
achieve the proof of concept
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase I Clinical Trial for Evaluating the Safety Tolerance and Efficacy of GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
Detailed Description:
This is an open-label dose escalationexpansion study to assess the safety tolerability and efficacy of CART cell in patients 18 years of age with relapsed or refractory advanced hepatocellular carcinoma Patients who meet the eligibility criteria will receive cell infusion The study will include the following sequential phases screening pre-treatment cell product preparation lymphodepleting chemotherapy treatment and follow up
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None